[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
Borets OG, Govorukhina NF, Zverev KV, Boiko AN
Zh Nevrol Psikhiatr Im S S Korsakova. 2016; 116(2. Vyp. 2. Rassejannyyj skleroz):63-67. PMID: 27070363.Abstract